ATR inhibitors have been shown to be synthetic lethal with DNA repair defects caused by ATM, TP53 or Rad51 loss in cancer cells (31–34), which prompted us to test whether they would be active against IDH1/2-mutant cells. The gene discussed is TP53; the disease is cancer.